Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 9/20 | 0.36 |
| ▸ | TDO2 | P48775 | 9/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958741 | 0.91 | RECQL (0.35) | RECQLCYP11B2PDE5APDE4APDE4B | |
| SCHEMBL27873115 | 0.88 | GCK (0.34) | RECQLPDE5APDE4APDE4BPDE4C | |
| SCHEMBL1962077 | 0.88 | PDE5A (0.38) | RECQLIDO1TDO2PDE5APDE4A | |
| SCHEMBL1962048 | 0.87 | ALDH1A1 (0.39) | RECQLIDO1TDO2PDE5APDE4A | |
| SCHEMBL1961925 | 0.85 | FKBP1A (0.36) | RECQLIDO1TDO2HTR6 | |
| SCHEMBL1961549 | 0.85 | IDO1 (0.36) | RECQLIDO1TDO2ALDH1A1HTR6 | |
| SCHEMBL1958810 | 0.85 | SMN1; SMN2 (0.35) | RECQLIDO1TDO2PDE5APDE4A | |
| SCHEMBL1961542 | 0.85 | RECQL (0.45) | RECQLIDO1TDO2PDE5APDE4A | |
| SCHEMBL1962889 | 0.84 | AADAT (0.34) | RECQLIDO1TDO2PDE5APDE4A | |
| SCHEMBL1959421 | 0.83 | KDM4E (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| CN-102686587-A | Azaindole glucokinase activators | HOFFMANN LA ROCHE | 2012-09-19 | — | — | CN | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | RECQL 3296/4885IDO1 1537/4885TDO2 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.